| Date Filed | Type | Description |
| 07/18/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/14/2023 |
SC 13G/A
| Logos Global Management LP reports a 4.8% stake in Bicycle Therapeutics plc |
| 09/28/2022 |
SC 13G
| Logos Global Management LP reports a 7% stake in Allakos Inc. |
| 05/02/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 03/18/2022 |
SC 13G
| Logos Global Management LP reports a 6.9% stake in IDEAYA Biosciences, Inc. |
| 02/15/2022 |
SC 13G/A
| Logos Global Management LP reports a 4.6% stake in Harpoon Therapeutics, Inc. |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| Logos Global Management LP reports a 5.7% stake in Dyne Therapeutics, Inc. |
| 02/14/2022 |
SC 13G/A
| Logos Global Management LP reports a 3% stake in Bicycle Therapeutics plc |
| 02/14/2022 |
SC 13G/A
| Logos Global Management LP reports a 3% stake in Kezar Life Sciences, Inc. |
| 02/14/2022 |
SC 13G/A
| Logos Global Management LP reports a 0% stake in Viridian Therapeutics, Inc. |
| 02/14/2022 |
SC 13G/A
| Logos Global Management LP reports a 0.4% stake in Cogent Biosciences, Inc. |
| 02/14/2022 |
SC 13G/A
| Logos Global Management LP reports a 0% stake in Nkarta, Inc. |
| 01/26/2022 |
SC 13G/A
| Logos Global Management LP reports a 0% stake in Eledon Pharmaceuticals, Inc. |
| 12/27/2021 |
SC 13G
| Logos Global Management LP reports a 5.6% stake in Harpoon Therapeutics, Inc. |
| 12/02/2021 |
SC 13G
| Logos Global Management LP reports a 3.4% stake in Compass Pathways plc |
| 11/15/2021 |
SC 13G
| Logos Global Management LP reports a 3.3% stake in Atreca, Inc. |
| 09/29/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 09/13/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 09/09/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 08/16/2021 |
SC 13G
| Logos Global Management LP reports a 7.6% stake in Dyne Therapeutics, Inc. |
| 08/13/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/28/2021 |
SC 13G
| Logos Global Management LP reports a 6.2% stake in Bicycle Therapeutics plc |
| 07/28/2021 |
SC 13G
| Logos Global Management LP reports a 5.2% stake in Kezar Life Sciences, Inc. |
| 06/15/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 12/03/2020 |
SC 13D
| Logos Global Management LP reports a 9.4% stake in Olema Pharmaceuticals, Inc. |
| 11/19/2020 |
SC 13G/A
| Logos Global Management LP reports a 10% stake in Cogent Biosciences, Inc. |
| 11/16/2020 |
SC 13G/A
| Logos Global Management LP reports a 14.1% stake in Miragen Therapeutics, Inc. |
| 11/09/2020 |
SC 13G
| Logos Global Management LP reports a 15.7% stake in Novus Therapeutics, Inc. |
| 11/09/2020 |
SC 13G
| Logos Global Management LP reports a 8.8% stake in Miragen Therapeutics, Inc. |
| 10/22/2020 |
SC 13G
| Logos Global Management LP reports a 4.3% stake in Celldex Therapeutics, Inc. |
| 09/08/2020 |
SC 13G
| Logos Global Management LP reports a 5% stake in Unum Therapeutics, Inc. |
| 09/01/2020 |
SC 13G
| Logos Global Management LP reports a 5.9% stake in Nkarta, Inc. |
| 08/31/2020 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |